Cargando…

Pan-cancer deconvolution of tumour composition using DNA methylation

The nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic response. Here, using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the integrated analysis of tumour composition and genomics across a wide spectrum of solid...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakravarthy, Ankur, Furness, Andrew, Joshi, Kroopa, Ghorani, Ehsan, Ford, Kirsty, Ward, Matthew J., King, Emma V., Lechner, Matt, Marafioti, Teresa, Quezada, Sergio A., Thomas, Gareth J., Feber, Andrew, Fenton, Tim R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089972/
https://www.ncbi.nlm.nih.gov/pubmed/30104673
http://dx.doi.org/10.1038/s41467-018-05570-1
_version_ 1783347111962607616
author Chakravarthy, Ankur
Furness, Andrew
Joshi, Kroopa
Ghorani, Ehsan
Ford, Kirsty
Ward, Matthew J.
King, Emma V.
Lechner, Matt
Marafioti, Teresa
Quezada, Sergio A.
Thomas, Gareth J.
Feber, Andrew
Fenton, Tim R.
author_facet Chakravarthy, Ankur
Furness, Andrew
Joshi, Kroopa
Ghorani, Ehsan
Ford, Kirsty
Ward, Matthew J.
King, Emma V.
Lechner, Matt
Marafioti, Teresa
Quezada, Sergio A.
Thomas, Gareth J.
Feber, Andrew
Fenton, Tim R.
author_sort Chakravarthy, Ankur
collection PubMed
description The nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic response. Here, using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the integrated analysis of tumour composition and genomics across a wide spectrum of solid cancers. Initially studying head and neck squamous cell carcinoma, we identify two distinct tumour subgroups: ‘immune hot’ and ‘immune cold’, which display differing prognosis, mutation burden, cytokine signalling, cytolytic activity and oncogenic driver events. We demonstrate the existence of such tumour subgroups pan-cancer, link clonal-neoantigen burden to cytotoxic T-lymphocyte infiltration, and show that transcriptional signatures of hot tumours are selectively engaged in immunotherapy responders. We also find that treatment-naive hot tumours are markedly enriched for known immune-resistance genomic alterations, potentially explaining the heterogeneity of immunotherapy response and prognosis seen within this group. Finally, we define a catalogue of mediators of active antitumour immunity, deriving candidate biomarkers and potential targets for precision immunotherapy.
format Online
Article
Text
id pubmed-6089972
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60899722018-08-15 Pan-cancer deconvolution of tumour composition using DNA methylation Chakravarthy, Ankur Furness, Andrew Joshi, Kroopa Ghorani, Ehsan Ford, Kirsty Ward, Matthew J. King, Emma V. Lechner, Matt Marafioti, Teresa Quezada, Sergio A. Thomas, Gareth J. Feber, Andrew Fenton, Tim R. Nat Commun Article The nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic response. Here, using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the integrated analysis of tumour composition and genomics across a wide spectrum of solid cancers. Initially studying head and neck squamous cell carcinoma, we identify two distinct tumour subgroups: ‘immune hot’ and ‘immune cold’, which display differing prognosis, mutation burden, cytokine signalling, cytolytic activity and oncogenic driver events. We demonstrate the existence of such tumour subgroups pan-cancer, link clonal-neoantigen burden to cytotoxic T-lymphocyte infiltration, and show that transcriptional signatures of hot tumours are selectively engaged in immunotherapy responders. We also find that treatment-naive hot tumours are markedly enriched for known immune-resistance genomic alterations, potentially explaining the heterogeneity of immunotherapy response and prognosis seen within this group. Finally, we define a catalogue of mediators of active antitumour immunity, deriving candidate biomarkers and potential targets for precision immunotherapy. Nature Publishing Group UK 2018-08-13 /pmc/articles/PMC6089972/ /pubmed/30104673 http://dx.doi.org/10.1038/s41467-018-05570-1 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Chakravarthy, Ankur
Furness, Andrew
Joshi, Kroopa
Ghorani, Ehsan
Ford, Kirsty
Ward, Matthew J.
King, Emma V.
Lechner, Matt
Marafioti, Teresa
Quezada, Sergio A.
Thomas, Gareth J.
Feber, Andrew
Fenton, Tim R.
Pan-cancer deconvolution of tumour composition using DNA methylation
title Pan-cancer deconvolution of tumour composition using DNA methylation
title_full Pan-cancer deconvolution of tumour composition using DNA methylation
title_fullStr Pan-cancer deconvolution of tumour composition using DNA methylation
title_full_unstemmed Pan-cancer deconvolution of tumour composition using DNA methylation
title_short Pan-cancer deconvolution of tumour composition using DNA methylation
title_sort pan-cancer deconvolution of tumour composition using dna methylation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089972/
https://www.ncbi.nlm.nih.gov/pubmed/30104673
http://dx.doi.org/10.1038/s41467-018-05570-1
work_keys_str_mv AT chakravarthyankur pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT furnessandrew pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT joshikroopa pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT ghoraniehsan pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT fordkirsty pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT wardmatthewj pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT kingemmav pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT lechnermatt pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT marafiotiteresa pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT quezadasergioa pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT thomasgarethj pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT feberandrew pancancerdeconvolutionoftumourcompositionusingdnamethylation
AT fentontimr pancancerdeconvolutionoftumourcompositionusingdnamethylation